Nevertheless, in a network meta-analysis comparing short-acting and long-acting GLP-1RAs when used in conjunction with basal insulin, long-acting GLP-1RAs resulted in significantly greater reductions in glycated hemoglobin (HbA1c), fasting plasma glucose, and body weight compared to short-acting GLP-1RAs, with better gastrointestinal tolerability [15]
Pharmacologic treatment of cancer-related fatigue
It works by: Suppressing appetite Slowing gastric emptying Improving insulin sensitivity Enhancing fat metabolism With consistent use and proper guidance, tirzepatide has helped many patients achieve significant and sustained weight loss
Typical dose starts with 3 mg once daily for 30 days to acclimate, then increase to 7 mg
No large-scale human safety trials have been published
If you are considering GLP-1 Injections or want more information, contact us today at 337-534-4410